Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Oncotarget|September 9, 2017
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesFederica Costa, Rosanna Vescovini, Marina Bolzoni, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 23, 2025
Successful treatment with Rezafungin following Micafungin for relapsing Rasamsonia argillacea species complex pneumonia in a patient with bronchiectasis: a case reportHugo Bes-Berlandier, Noémie Coron, Heloise Pottier, et al.
Annals of Hematology|April 30, 2024
Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experienceNicolò Danesin, Laura Bonaldi, Annalisa Martines, et al.
Frontiers in Oncology|November 1, 2021
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell LymphomaSabrina Manni, Anna Fregnani, Laura Quotti Tubi, et al.
Cancers|September 9, 2022
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple MyelomaAnna Fregnani, Lara Saggin, Ketty Gianesin, et al.
Medical Oncology (Northwood, London, England)|July 15, 2026
DLBCL-microenvironment interactions: cytokine profiling and ECM-mediated ibrutinib resistance in a 3D bone-based modelJessica Ceccato, Maria Piazza, Giulia Gualtiero, et al.
Plos One|October 3, 2013
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cellsSabrina Manni, Alessandra Brancalion, Elisa Mandato, et al.
Cancers|November 13, 2021
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic LeukemiaFederica Frezzato, Andrea Visentin, Filippo Severin, et al.
Oncotarget|January 19, 2017
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathwaysSabrina Manni, Marilena Carrino, Martina Manzoni, et al.
Frontiers in Oncology|July 2, 2021
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma PatientsGregorio Barilà, Laura Pavan, Susanna Vedovato, et al.
Pageof 5